
INSP Stock Forecast & Price Target
INSP Analyst Ratings
Bulls say
Inspire Medical Systems has demonstrated significant growth potential as evidenced by a notable 56% increase in spending in the third quarter of 2025, with expectations for continued investment into 2026, which historically has driven awareness and procedural uptake. The company's advertising expenses rose to $100 million in 2023, a 34% year-over-year increase, indicating a strong commitment to expanding market presence and supporting revenue growth. Additionally, management has indicated plans to increase average selling prices (ASP) starting in calendar year 2026 alongside improved reimbursement prospects, which could lead to higher volumes and enhanced profitability.
Bears say
Inspire Medical Systems is facing a negative outlook primarily due to a slowdown in advertising expenditures, which decreased by 5% year-over-year for 2024 and are projected to decline by 6% in the first half of 2025. The anticipated launch of the Inspire 5 product has encountered challenges that have prompted management to lower its revenue and earnings per share outlook, indicating a slower adoption than previously expected. Furthermore, operational expenditures were less than industry expectations, primarily due to significant cuts in research and development and selling, general, and administrative expenses, raising concerns about the company's growth trajectory and overall stock valuation.
This aggregate rating is based on analysts' research of Inspire Medical Systems Inc and is not a guaranteed prediction by Public.com or investment advice.
INSP Analyst Forecast & Price Prediction
Start investing in INSP
Order type
Buy in
Order amount
Est. shares
0 shares